News
OCUP
1.530
-0.65%
-0.010
Press Release: Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
Ocuphire Pharma, Inc. Is a clinical-stage company focused on developing novel therapies for the treatment of retinal and refractive eye disorders. Daniel Su, M.D. Will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting in Seattle, Washington. The company's lead product candidate is an oral inhibitor of Ref-1 for the treating of non-proliferative diabetic retinopathy.
Dow Jones · 3d ago
Weekly Report: what happened at OCUP last week (0415-0419)?
Weekly Report · 3d ago
Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
TipRanks · 04/17 20:32
Weekly Report: what happened at OCUP last week (0408-0412)?
Weekly Report · 04/15 09:58
12 Health Care Stocks Moving In Thursday's After-Market Session
Ontrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. Ocuphire Pharma stock rose 7.82% and Lyell Immunopharma stock rose by 7.5%. Motus GI Hldgs stock declined by 32.6% during the after- market session.
Benzinga · 04/11 20:31
FIRST PATIENT ENROLLED IN LYNX-2 PHASE 3 STUDY EVALUATING PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% (PS) FOR THE TREATMENT OF DECREASED VISUAL ACUITY UNDER LOW LIGHT CONDITIONS FOLLOWING KERATOREFRACTIVE SURGERY
Reuters · 04/11 14:03
Weekly Report: what happened at OCUP last week (0401-0405)?
Weekly Report · 04/08 10:00
UPDATE 2-Lenz Therapeutics' eye drop helps improve vision in late-stage study
Lenz Therapeutics' eye drop helps improve vision in late-stage study. Shares of the company gained as much as 17% earlier in the day. The once-daily eye drop is being tested to treat presbyopia, a common age-related eye disorder. The company plans to submit a U.S. Marketing application for the drug.
Reuters · 04/03 11:27
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)
TipRanks · 04/02 11:20
Ocuphire Announces the US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Ocuphire Pharma, Inc. Announced the U.S. Commercial launch of RYZUMVI (phentolamine ophthalmic solution) by its partner Viatris Inc. The company is focused on developing novel therapies for the treatment of patients with retinal and refractive eye disorders.
Benzinga · 04/01 11:17
Weekly Report: what happened at OCUP last week (0325-0329)?
Weekly Report · 04/01 09:59
Ocuphire Pharma Engages Investors with Presentation Update
TipRanks · 03/27 20:44
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Insider transactions for penny stocks indicate confidence or concern around the company's prospects. FTC Solar, Inc. And Ocuphire Pharma have recently had notable insider transactions. The Dow Jones index closed lower by over 150 points on Monday. FTC solar and Design Therapeutics are among the recent penny stocks with notable insider trades.
Benzinga · 03/26 11:37
Weekly Report: what happened at OCUP last week (0318-0322)?
Weekly Report · 03/25 10:01
Ocuphire Pharma Is Maintained at Buy by Alliance Global Partners
Dow Jones · 03/20 12:20
Ocuphire Pharma Price Target Cut to $20.00/Share From $24.00 by Alliance Global Partners
Dow Jones · 03/20 12:20
Alliance Global Partners Maintains Buy on Ocuphire Pharma, Lowers Price Target to $20
Benzinga · 03/20 12:10
Weekly Report: what happened at OCUP last week (0311-0315)?
Weekly Report · 03/18 10:00
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023
Ocuphire Pharma reported earnings per share of -21 cents for the fourth quarter of 2023. The company reported revenue of $1.69 million. This was 68.39% worse than the analyst estimate for revenue in the same period. Ocuphir Pharma reported results for the third quarter of 2018.
Investorplace · 03/15 15:53
Ocuphire Pharma Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 03/11 11:46
More
Webull provides a variety of real-time OCUP stock news. You can receive the latest news about Ocuphire Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCUP
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.